Pembrolizumab - Merck & Co
At a glance
- Drug Originator Immune-Onc Therapeutics; Merck & Co; The Leukemia & Lymphoma Society
- Drug Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Programmed cell death 1 receptor antagonists
- USA Patent Applicants MERCK SHARP DOHME
- USA Patents 352
- BLAs 1
- International Patents 4,456

Disclaimer